Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands.

PLoS One · 2016 · PMC5077099 · PMID 27776137

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

Furthermore, this study simulated the occurrences of all MCRBs further subdivided into ICHs, other MBs, CRNMBs and deaths from bleeding, however, the meta-analysis of the RE-COVER trials indicated that there was only a marginally significant reduction of MBs observed in the double-dummy period in dabigatran arm compared to VKA.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.